ARAF

Across TCGA pan-cancer cohorts, ARAF Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARAF data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ARAF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARAF expression acts as an unfavorable survival marker, although some lineages such as UCEC and MESO show a favorable association.

LIHC, STAD, and SKCM are the cancer types where ARAF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.118	0.783	<.001	21	view →
STAD	OS	Median	All	0.221	0.689	.009	12	view →
SKCM	DFS	Median	II,III,IV	0.124	0.686	<.001	9	view →
UCEC	DFS	Median	All	0.922	0.627	.030	4	view →
MESO	DFS	Median	All	1.000	0.179	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARAF–LIHC (OS)

Open the LIHC breakdown →